Coneys, R and Wood, IC orcid.org/0000-0003-1886-2533 (2020) Alzheimer’s disease: the potential of epigenetic treatments and current clinical candidates. Neurodegenerative Disease Management, 10 (3). nmt-2019-0. pp. 543-558. ISSN 1758-2024
Abstract
Alzheimer’s disease is a progressive and fatal neurodegenerative disease affecting 50 million people worldwide, characterized by memory loss and neuronal degeneration. Current treatments have limited efficacy and there is no cure. Alzheimer's is likely caused by a combination of factors, providing several potential therapeutic targets. One area of interest is the epigenetic regulation of gene expression within the brain. Epigenetic marks, including DNA methylation and histone modifications, show consistent changes with age and in those with Alzheimer’s. Some epigenetic regulation has been linked to disease pathology and progression and are the focus of current research. Epigenetic regulators might make promising therapeutic targets yet challenges need to be overcome to generate an efficacious drug lacking deleterious side effects.
Metadata
Item Type: | Article |
---|---|
Authors/Creators: |
|
Copyright, Publisher and Additional Information: | © 2020 Future Medicine Ltd. This is an author produced version of an article published in Neurodegenerative Disease Management. Uploaded in accordance with the publisher's self-archiving policy. |
Keywords: | acetylation; ageing; Alzheimer's; chromatin; dementia; epigenetics; histone; methylation; ncRNA |
Dates: |
|
Institution: | The University of Leeds |
Academic Units: | The University of Leeds > Faculty of Biological Sciences (Leeds) > School of Biomedical Sciences (Leeds) |
Depositing User: | Symplectic Publications |
Date Deposited: | 14 Sep 2020 13:30 |
Last Modified: | 17 Jun 2021 00:38 |
Status: | Published |
Publisher: | Future Medicine |
Identification Number: | 10.2217/nmt-2019-0034 |
Open Archives Initiative ID (OAI ID): | oai:eprints.whiterose.ac.uk:165469 |